Syngene Expands Global Biologics Footprint with First U.S. Site
Slice of Manufacturing Team
Mar 17, 2025
Key Highlights:
- Syngene acquires a biologics facility in Baltimore, USA from Emergent BioSolutions.
- Increases global single-use bioreactor capacity to 50,000L for biologics R&D and manufacturing.
- Expands U.S. presence, supporting human and animal health market segments.
- Investment of $50M, fully funded through internal accruals and cash.
- Facility to be operational by H2 2025, creating local jobs and boosting biotech innovation.
Source: PR Newswire
Quotes
“ "With one of the largest biologics R&D teams and commercial-scale manufacturing capabilities in both India and the USA, we now offer a compelling and flexible solution for global pharma and biotech customers." ”
Peter Bains, CEO Designate at Syngene International Ltd
Why This Matters:
This acquisition underscores Syngene’s commitment to expanding its global biologics footprint and strengthening U.S. biopharmaceutical manufacturing. The new site enhances supply chain resilience while supporting domestic innovation in monoclonal antibody (mAb) production. Additionally, the move bolsters U.S.-India economic collaboration and meets the increasing demand for onshore biologics production for human and animal health.
